Friday October 31, 2014




Home »  News »  Health

Sask. joins Atlantic provinces and Ontario in stopping funding for OxyContin

TORONTO - Saskatchewan has joined Ontario and the Atlantic provinces in taking steps to stop funding the painkiller OxyContin, and a new version of the drug, OxyNeo.

The changes coincide with plans by the manufacturer, Purdue Pharma Canada of Pickering, Ont., to discontinue producing OxyContin at the end of February and replace it with OxyNeo.

Starting at the end of the month, Saskatchewan will only pay for OxyNeo for cancer or palliative care patients. Existing patients who have received coverage of OxyContin in the three months prior to March 1 will be eligible for coverage of OxyNeo.

Earlier Tuesday, Nova Scotia Health Minister Maureen MacDonald said cancer patients and those in palliative care who are already prescribed OxyContin would continue to receive the drug.

In a notice released Friday, the Ontario Health Ministry said OxyNeo would be funded through the province's Exceptional Access Program, which places prescriptions of the drug under tighter controls.

Health Canada has warned that OxyContin, taken in pill form, is a long-acting form of the highly addictive opioid oxycodone. But when the pill is chewed or crushed, then injected or inhaled, it produces a ``heroin-like euphoria.

OxyNeo will also be made with oxycodone, but it's formulated to make abuse more difficult. The tablet is hard to crush, and when added to liquid, it forms a thick gel that stops oxycodone from being extracted for injection.


Comments


NOTE: To post a comment in the new commenting system you must have an account with at least one of the following services: Disqus, Facebook, Twitter, Yahoo, OpenID. You may then login using your account credentials for that service. If you do not already have an account you may register a new profile with Disqus by first clicking the "Post as" button and then the link: "Don't have one? Register a new profile".

The Yorkton This Week welcomes your opinions and comments. We do not allow personal attacks, offensive language or unsubstantiated allegations. We reserve the right to edit comments for length, style, legality and taste and reproduce them in print, electronic or otherwise. For further information, please contact the editor or publisher, or see our Terms and Conditions.

blog comments powered by Disqus


Quick Vote

Survey results are meant for general information only, and are not based on recognised statistical methods.


Markets





LOG IN



Lost your password?